Von Gierke Disease

Not yet reviewed

This information is AI generated and has not yet been reviewed by a specialist physician. AI can make mistakes.

Disease overview

Deficiency in G6Pase (GSD Type 1a) or G6P transporter (GSD Type 1b) impairs terminal step in both glycogenolysis and gluconeogenesis preventing glycogen use and lowering blood glucose.

Common symptoms

Presents in first few months of life with severe hypoglycemialactic acidosishyperuricemiahepatomegaly and nephromegaly (from glycogen and fat deposition in liver and kidneys). Patient may have full cheeksrelatively thin extremitiesshort statureand protuberant abdomen.

When to suspect

How to test

ZebraMD is partnering with Ambry Genetics for clinical-grade whole genome testing for rare diseases. Ambry accepts insurance. If you don’t have a physician to order this test, join our referral list and our team will reach out.

Treatment

  • Recommendation 1

    Small, frequent feedings spread over 24 hours with supplemental cornstarch. Overnight feeding tube may be needed to avoid hypoglycemia. Avoid sucrose, galactose, fructose, high fructose corn syrup, honey, maple syrup, molasses, agave nectar, and sorbitol. Complete multivitamin likely needed given dietary restrictions.

Primary care

  • Recommendation 1

    Kidney and liver ultrasound, labs (including CBC, CMP, LFTs, coagulation panel), at least annually. Bone density every 1-2 years.

Further support

  • Recommendation 1

    Several large academic medical centers have dedicated Glycogen Storage Disorder programs/clinics. Genetic counseling is recommended. The Scientific Advisory Board of the Association for Glycogen Storage Disease offers a list of hospitals with GSD-focused clinics. Referral to Medical Genetics Department, if available. Initial virtual care is also available through organizations like TeleRare Health.

Clinical trials

Clinical Trials

Sources

No data available

Interested in learning more about Von Gierke Disease?

Follow to receive regular updates to the latest research development on this disease via email newsletter.